Suicide risk among cancer survivors: Head and neck versus other cancers.

Authors

null

Nosayaba Osazuwa-Peters

Saint Louis University School of Medicine, St. Louis, MO

Nosayaba Osazuwa-Peters , Matthew C Simpson , Longwen Zhao , Eric Adjei Boakye , Stephanie I Olomukoro , Mark A Varvares

Organizations

Saint Louis University School of Medicine, St. Louis, MO, Saint Louis University College for Public Health and Social Justice, St. Louis, MO, Saint Louis University Center for Health Outcomes Research, St. Louis, MO, Harvard Medical School, Boston, MA

Research Funding

Other

Background: While head and neck cancer (HNC) only accounts for 4% of new cancer cases in the United States, incidence of HNC-associated suicide may be significantly higher due to quality of life issues associated with HNC survivorship. This study estimated incidence of HNC-associated suicide versus other common cancers, and quantified suicide rate among HNC survivors compared with non-HNC. Methods: We queried the Surveillance, Epidemiology and End Results 18 database from 2000-2014 for all cancer deaths confirmed as suicide. Mortality rates from suicide was estimated for the 21 most common cancers in the United States, including HNC. Negative binomial regression estimated mortality rate ratios (MRRs) and 95% confidence intervals (CIs), between HNC and the other 20 other cancers combined, and as individual sites. Models were stratified by sex (when applicable), controlling for race, marital status, age, year and stage of diagnosis. Results: There were 4,769 suicides observed among 4,613,123 cancer survivors from 2000-2014, yielding an incidence rate of 23.6 suicides per 100,000 person-years. Combined, all other cancers had a 45% decreased suicide ratio compared to HNC for both males (MRR = 0.55, 95% CI 0.48, 0.64) and females (MRR = 0.55, 95% CI 0.37, 0.81). For specific cancer sites, only pancreatic cancer had a higher mortality rate due to suicide than HNC (86.4 suicides per 100,000 person-years, versus 63.4 suicides per 100,000 person-years). Stratified by gender, only male pancreatic cancer survivors had a significantly higher suicide MRR compared with HNC (MRR = 1.54, 95% CI 1.23, 1.90). For females, all cancer sites (including pancreas) had either significantly or insignificantly lower suicide MRR compared with HNC. Conclusions: Risk of suicide is significantly higher among HNC survivors compared to all other cancers, except pancreatic cancer. Our findings confirm that HNC survivors are prime candidates for lifelong psychosocial surveillance.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2018 Cancer Survivorship Symposium

Session Type

Oral Abstract Session

Session Title

Oral Abstract Session B

Track

Chronic Anti-Cancer Therapy,Late- and Long-term Effects/Comorbidities,Health Promotion,Psychosocial Issues,Care Coordination, Cost, and Education,Communication and Transitions,Risk Assessment

Sub Track

Psychological and Social Well-being

Citation

J Clin Oncol 36, 2018 (suppl 7S; abstr 146)

DOI

10.1200/JCO.2018.36.7_suppl.146

Abstract #

146

Abstract Disclosures

Similar Abstracts

Abstract

2020 ASCO Virtual Scientific Program

Marital status and suicide as a competing cause of mortality among cancer survivors.

First Author: Nosayaba Osazuwa-Peters

Abstract

2024 ASCO Quality Care Symposium

Opioid tapering and discontinuation for head and neck cancer (HNC) survivors.

First Author: Talya Salz

Abstract

2018 ASCO Annual Meeting

Gender differences and trends in suicide risk among cancer survivors.

First Author: Nosayaba Osazuwa-Peters

Abstract

2022 ASCO Annual Meeting

The future landscape of cancer incidence and mortality until 2036 in the Russian Federation.

First Author: Ilya Tsimafeyeu